Central antinociception induced by ketamine is mediated by endogenous opioids and μ- And δ-opioid receptors

Brain Research

Volumn 1562, Issue , 2014, Pages 69-75

  Pacheco, Daniela Da Fonseca ^a   Romero, Thiago Roberto Lima ^a   Duarte, Igor Dimitri Gama ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Central antinociception; Endogenous opioid; Ketamine

Indexed keywords

BESTATIN; CLOCINNAMOX; DELTA OPIATE RECEPTOR; ENDORPHIN; KETAMINE; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; AMINOPEPTIDASE; ANALGESIC AGENT; CINNAMIC ACID DERIVATIVE; ENZYME INHIBITOR; KAPPA OPIATE RECEPTOR; LEUCINE; MORPHINE DERIVATIVE; NALTREXONE; NARCOTIC ANTAGONIST; NORBINALTORPHIMINE; OPIATE PEPTIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CENTRAL ANTINOCICEPTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; TAIL FLICK TEST; THERMAL STIMULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; HEAT; METABOLISM; NOCICEPTION; NOCICEPTIVE PAIN; PHYSIOLOGY;

MUS;

AMINOPEPTIDASES; ANALGESICS; ANIMALS; BRAIN; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HOT TEMPERATURE; KETAMINE; LEUCINE; MALE; MICE; MORPHINE DERIVATIVES; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NOCICEPTIVE PAIN; OPIOID PEPTIDES; PAIN PERCEPTION; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 84899454887     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2014.03.026     Document Type: Article

References (55)

1. A.K. Baker, V.L. Hoffmann, and T.F. Meert Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain Pharmacol. Biochem. Behav. 74 2002 73 86
2. M.L. Banks, J.E. Folk, K.C. Rice, and S.S. Negrus Selective enhancement of fentanyl-induced by the delta agonist SNC162 but not by ketamine in rhesus monkeys: further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics Pharmacol. Biochem. Behav. 97 2010 205 212
3. A.I. Basbaum, and H.L. Fields Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry Annu. Rev. Neurosci. 7 1984 309 338
4. A. Baumeister, and C. Advokat Evidence for a supraspinal mechanism in the opioid-mediated antinociceptive effect of ketamine Brain Res. 566 1991 351 353
5. R.M. Bowker, and R.P. Dilts Distribution of mu-opioid receptors in the nucleus raphe magnus and nucleus gigantocellularis: a quantitative autoradiographic study Neurosci. Lett. 88 1988 247 252
6. T.F. Burke, J.H. Woods, and J.W. Lewis Medzihradsky F irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice J. Pharmacol. Exp. Ther. 271 1994 715 721
7. A.R. Campos, F.A. Santos, and V.S. Rao Ketamine-induced potentiation of morphine analgesia in rat tail-flick test: role of opioid-, alpha2-adrenoceptors and ATP-sensitive potassium channels Biol. Pharm. Bull. 29 2006 86 89
8. T. Crisp, J.M. Perrotti, D.L. Smith, J.L. Stafinsky, and D. Smith The local monoaminergic dependency of spinal ketamine Eur. J. Pharmacol. 194 1991 167 172
9. F.E. D'amour, and D.L. Smith A method for determinig loss osf pain sensation J. Pharmacol. Exp. Ther. 72 1941 74 79
10. U. Eichenberger, F. Neff, G. Sveticic, S. Björgo, S. Petersen-Felix, L. Arendt-Nielsen, and M. Curatolo Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain andsensory thresholds Anesth. Analg. 106 2008 1265 1273
11. A.K. Gilbert, and K.B. Franklin GABAergic modulation of descending inhibitory systems from the rostral ventromedial medulla (RVM). Dose-response analysis of nociception and neurological deficits Pain 90 2001 25 36
12. V.M Goettl, and A.A. Larson Antinociception induced by 3-((±)-2-carboxypiperazine-4-yl-propyl-1-phosphonic acid (CPP), an N-methyl-d-aspartate (NMDA) competitive antagonist, plus 6,7-dinitroquinoxaline- 2,3-dione (DNQX), a non-NMDA antagonist, differs from that induced by MK-801 plus DNQX Brain Res. 642 1994 334 338
13. A. Gupta, L.A. Devi, and I. Gomes Potentiation of μ-opioid receptor-mediated signaling by ketamine J. Neurochem. 119 2011 294 302
14. H.B. Gutstein, A. Mansour, S.J. Watson, H. Akil, and H.L. Fields Mu and kappa opioid receptors in periaqueductal gray and rostral ventromedial medulla Neuroreport 9 1998 1777 1781
15. L.S. Guzzo, A.C. Perez, T.R. Romero, A.O. Azevedo, and I.D. Duarte Cafestol, a coffee-specific diterpene, induces peripheral antinociception mediated by endogenous opioid peptides Clin. Exp. Pharmacol. Physiol. 39 2012 412 416
16. T.J. Haley, and W.G. Mccormick Pharmacological effects produced by intracerebroventricular injection of drugs in the conscious mouse Br. J. Pharmacol. Chemother. 12 1957 12 15
17. J.E. Haley, A.F. Sullivan, and A.H. Dickenson Evidence for spinal N-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the rat Brain Res. 518 1990 218 226
18. L. Hersh Degradation of enkephalins: the search for an enkephalinase Mol. Cel. Biochem. 47 1982 35 43
19. V.L.H. Hoffmann, K.M. Vermeyen, H.F. Adriaensen, and T.F. Meert Effects of NMDA receptor antagonists on opioid-induced respiratory depression and acute antinociception in rats Pharmacol. Biochem. Behav. 74 2003 933 941
20. G. Horvath, G. Joo, I. Dobos, W. Klimscha, G. Toth, and G. Benedek The synergistic antinociceptive interactions of endomorphin1 with dexmedetomidine and/orS(+)-ketamine in rats Anesth. Analg. 93 2001 1018 1024
21. M.R. Jia, T. Wei, and W.F. Xu The analgesic activity of bestatin as a potent APN inhibitor Front. Neurosci. 4 2010 1 10
22. R.G. Kalb, and A.J. Fox Synchronized overproduction of AMPA, kainate, and NMDA glutamate receptors during human spinal cord development J. Comp. Neurol. 384 1997 200 210
23. A.E. Kalyuzhny, and M.W. Wessendorf Relationship of mu- and delta-opioid receptors to GABAergic neurons in the central nervous system, including antinociceptive brainstem circuits J. Comp. Neurol. 392 1998 528 547
24. B.I. Khalefa, M. Shaqura, M. Al-Khrasani, S. Fürst, S.A. Mousa, and M. Schäfer Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids Eur. J. Pain 16 2012 690 705
25. R. Kohrs, and M.E. Durieux Ketamine: teaching an old drug new tricks Anesth. Analg. 87 1998 1186 1193
26. M. Leandri, S. Leandri, M. Ghignotti, M. Cilli, and G. Lunardi The ITFR, impulsive tail flick reflex by short duration nociceptive stimuli J. Neurosci. Methods 15 2011 69 77
27. D. Le Bars, M. Gozariu, and S.W. Cadden Animal models of nociception Pharmacol. Rev. 53 2001 597 652
28. S. Le Guen, G. Catheline, M.C. Fournié-Zaluski, B.P. Roques, J.M. Besson, and J. Buritova Further evidence for the interaction of μ- and δ-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB 101 (S) Brain. Res. 967 2003 106 112
29. D. Lodge, and K.M. Johnson Noncompetitive excitatory amino acid receptor antagonists Trends Pharmacol. Sci. 11 1990 81 86
30. K. Lutfy, S.X. Cai, R.M. Woodward, and E. Weber Antinociceptive effects of NMDA and non-NMDA receptor antagonists in the tail flick test in mice Pain 70 1997 31 40
31. J. Mao NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity Brain Res. Rev. 30 1999 289 304
32. M.J. Millan The induction of pain: an integrative review Prog. Neurobiol. 57 1999 1 164
33. J. Näsström, U. Karlsson, and C. Post Antinociceptive actions of different classes of excitatory amino acids receptor antagonists in mice Eur. J. Pharmacol. 212 1992 21 29
34. M.M. Nieto, J. Wilson, J. Walker, J. Benavide, M.C. Fournié- Zaluski, B.P. Roques, and F. Noble Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management Neuropharmacology 41 2001 496 506
35. D.F. Pacheco, A. Klein, A.C. Perez, C.M. Pacheco, J.N. Francischi, G.M. Reis, and I.D. Duarte Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor Br. J. Pharmacol. 158 2009 225 231
36. C.G. Parsons, R. Gruner, J. Rozental, J. Millar, and D. Lodge Patch clamp studies on the kinetics and selectivity of N-methyl-D aspartate receptor antagonismby memantine (1-amino-3,5-dimethyladamantan) Neuropharmacology 32 1993 1337 1350
37. Z.W. Pavlovic, and R.J. Bodnar Opioid supraspinal analgesic synergy between the amygdala and periaqueductal gray in rats Brain Res. 779 1998 158 169
38. G.M. Pekoe, and D.J. Smith The involvement of opiate and monoaminergic neuronal systems in the analgesia effects of ketamine Pain 12 1982 57 73
39. P.S. Portoghese, M. Sultana, and A.E. Takemori Design of peptidomimetic delta opioid receptor antagonists using the message-address concept J. Med. Chem. 33 1990 1714 1720
40. J. Qian, S.D. Brown, and S.M. Carlton Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy Brain Res. 715 1996 51 62
41. G.M. Reis, D. Pacheco, A.C. Perez, A. Klein, M.A. Ramos, and I.D. Duarte Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of thecannabinoid receptor agonist anandamide Life Sci. 85 2009 351 356
42. K. Ren, G.M. Williams, J.L.K. Hylden, M.A. Ruda, and R. Dubner The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats Eur. J. Pharmacol. 219 1992 235 243
43. T.R. Romero, A.C. Perez, J.N. Francischi, and I.D.G. Duarte Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine Eur. J. Pharmacol. 7 2009 23 27
44. T.R. Romero, F. Pacheco Dda, and I.D. Duarte Xylazine induced central antinociception mediated by endogenous opioids and μ-opioid receptor, but not δ-or κ-opioid receptors Brain Res. 1506 2013 58 63
45. B.P. Roques, F. Noble, V. Daugé, M.C. Fournié-Zaluski, and A. Beaumont Neutral endopeptidase: structure, inhibition and experimental and clinical pharmacology Pharmacol. Rev. 45 1993 87 146
46. B.P. Roques Novel approaches to targeting neuropeptide systems Trends Pharmacol. Sci. 21 2000 475 483
47. R.B. Rothman, V. Bykov, A. Reid, B.R. De Costa, A.H. Newman, A.E. Jacobson, and K.C. Rice A brief study of the selectivity of norbinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro Neuropeptides 12 1988 181 187
48. E. Sarton, L.J. Teppema, C. Olievier, D. Nieuwenhuijs, H.W. Matthes, B.L. Kieffer, and A. Dahan The involvement of the mu-opioid receptor in ketamine-induced respiratory depression andantinociception Anesth. Analg. 93 2001 1495 1500
49. M. Satoh, and M. Minami Molecular pharmacology of the opioid receptors Pharmacol. Ther. 68 1995 343 364
50. V.K. Singh, K. Bajpai, S. Biswas, W. Haq, M.Y. Khan, and K.B. Mathur Molecular biology of opioid receptors: recent advances Neuroimmunomodulation 4 1997 285 297
51. D.J. Smith, J.M. Perotti, T. Crisp, M.E. Cabral, J.T. Long, and J.M. Scalziti The mu opiate receptor is responsible for descending pain inhibition originating in the periaqueductal gray region of the rat brain Eur. J. Pharmacol. 156 1988 47 54
52. M. Terashvili, L.F. Tseng, H.E. Wu, J. Narayanan, L.M. Hart, J.R. Falck, P.F. Pratt, and D.R. Harder Antinociception produced by 14,15- epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray J. Pharmacol. Exp. Ther. 326 2008 614 622
53. L.F. Tseng The β-endorphin-sensitive opioid ε-receptor-mediated antinociception Trends Pharmacol. Sci. 22 2001 623 630
54. T.L. Yaksh, N.R. Al-Rodhan, and T.S. Jensen Sites of action of opiates in production of analgesia Prog. Brain Res. 77 1988 371 394
55. T. Yamamoto, and T.L. Yaksh Comparison of the antinociceptive effects of pre- and post-treatment with intrathecal morphine and MK-801, an NMDA antagonist, on the formalin test in the rat Anesthesiology 77 1992 757 765